ED medication

搜索文档
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results - AngioDynamics (NASDAQ:ANGO), Aspire Biopharma Hldgs (NASDAQ:ASBP)
Benzinga· 2025-10-02 21:44
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.Following the market opening Thursday, the Dow traded up 0.15% to 46,510.40 while the NASDAQ rose 0.47% to 22,861.86. The S&P 500 also rose, gaining, 0.27% to 6,729.47.Check This Out: Cramer Says Arista’s ‘Doing So Well’ — But Snubs Sprouts For CostcoLeading and Lagging SectorsInformation technology shares jumped by 0.9% on Thursday.In trading on Thursday, real estate stocks fell by 0.6%.Top HeadlineAngioDynamics, ...
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
Accessnewswire· 2025-10-01 20:30
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization Future Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / October 1, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced pipeline progress and key milestones expected through the remainder of 2025 and early 2026. The company is focusing its pip ...